{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:06:40Z","timestamp":1785870400666,"version":"3.56.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ijtb.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T19:42:13Z","timestamp":1737229333000},"page":"517-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Overview of the tuberculosis vaccine development landscape"],"prefix":"10.1016","volume":"72","author":[{"given":"Banurekha","family":"Velayutham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2025.01.004_bib1","series-title":"Global Tuberculosis Report 2024","year":"2023"},{"key":"10.1016\/j.ijtb.2025.01.004_bib2","first-page":"56","article-title":"Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai","volume":"110","year":"1999","journal-title":"Indian J Med Res"},{"issue":"9","key":"10.1016\/j.ijtb.2025.01.004_bib3","doi-asserted-by":"crossref","first-page":"e1307","DOI":"10.1016\/S2214-109X(22)00283-2","article-title":"Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis","volume":"10","author":"Martinez","year":"2022","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.ijtb.2025.01.004_bib4","series-title":"WHO Preferred Product Characteristics for New Tuberculosis Vaccines","year":"2018"},{"key":"10.1016\/j.ijtb.2025.01.004_bib5","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.3389\/fmicb.2019.03154","article-title":"Clinical development of new TB vaccines: recent advances and next steps","volume":"10","author":"Hatherill","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijtb.2025.01.004_bib7","article-title":"Pipeline report","year":"2023","journal-title":"Tuberculosis vaccines."},{"issue":"46","key":"10.1016\/j.ijtb.2025.01.004_bib8","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1016\/j.vaccine.2020.09.055","article-title":"DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: a randomized controlled, double-blind phase 2b trial","volume":"38","author":"Munseri","year":"2020","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.ijtb.2025.01.004_bib9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s40121-023-00806-0","article-title":"Safety and immunogenicity of the ID93 + GLA-SE tuberculosis vaccine in BCG-vaccinated healthy adults: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"12","author":"Choi","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"3","key":"10.1016\/j.ijtb.2025.01.004_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(23)00501-7","article-title":"Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial","volume":"24","author":"Wajja","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"10.1016\/j.ijtb.2025.01.004_bib11","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/as01e vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijtb.2025.01.004_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ijtb.2025.01.004_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130540","article-title":"BCG revaccination boosts adaptive polyfunctional Th1\/Th17 and innate effectors in IGRA+ and IGRA- Indian adults","volume":"4","author":"Rakshit","year":"2019","journal-title":"JCI Insight"},{"issue":"2&3","key":"10.1016\/j.ijtb.2025.01.004_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4103\/ijmr.ijmr_1540_22","article-title":"Revisiting the Chingleput BCG vaccination trial for the impact of BCG revaccination on the incidence of tuberculosis disease","volume":"157","author":"Velayutham","year":"2023","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijtb.2025.01.004_bib15","article-title":"Bacillus calmette-gu\u00e9rin (BCG) revaccination and protection against tuberculosis: a systematic review","volume":"16","author":"Lawrence","year":"2014","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.ijtb.2025.01.004_bib16","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10096-020-03843-6","article-title":"Tuberculosis vaccine development: from classic to clinical candidates","volume":"39","author":"Li","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijtb.2025.01.004_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1211388","article-title":"Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges","volume":"14","author":"Morrison","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijtb.2025.01.004_bib19","series-title":"An Investment Case for New Tuberculosis Vaccines","year":"2022"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570725000216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570725000216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:08:31Z","timestamp":1758254911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570725000216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0019570725000216"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2025.01.004","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of the tuberculosis vaccine development landscape","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Tuberculosis Association of India. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}